Recombinant PD-1 anticorps

N° du produit ABIN7828483

Cet anticorps Lapin Monoclonal détecte spécifiquement PD-1 dans IHC et IF. Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour Recombinant PD-1 anticorps (ABIN7828483)

Antigène: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp PD-1 est non-conjugé

Application: Immunohistochemistry (IHC), Immunofluorescence (IF)

Clone: A115

Détail du produit anti-PD-1 anticorps

Fonction: Recombinant PD1 Monoclonal Antibody

Purification: Protein A purified

Immunogène: Synthetic peptide derived from the human PD1 protein

Isotype: IgG, kappa

Information d'application

Indications d'application: IHC 1:200-1:1000,IF 1:50

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: PBS, 50 % glycerol, 0.05 % Proclin 300, 0.05 % protein protectant.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.

Date de péremption: 12 months

Détails sur PD-1

Antigène: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Autre désignation: PD1

Sujet: SLEB,hSLE,Programmed Death,programmed cell death,Programmed cell death protein,Systemic lupus erythematosus susceptibility,hPD,PDCD1,CD279,PD-1,PD1,SLEB2,hPD-1,hPD-l,hSLE1,programmed cell death 1,PD 1,CD279 antigen,hPD 1,hPD l,PDCD 1,Programmed cell death 1 protein,Programmed Death-1,Protein PD 1,Protein PD-1,Systemic lupus erythematosus susceptibility 2,Programmed cell death protein 1,CD279,CD279 antigen,hPD 1,hPD l,hPD-1,hSLE1,PD 1,PD-1,PD1,PDCD 1,PDCD1,PDCD1,Programmed cell death 1,Programmed cell death 1 protein,Programmed cell death protein 1,Protein PD 1,Protein PD-1,SLEB2,Systemic lupus erythematosus susceptibility 2,The programmed cell death 1 protein (PD1) is an inhibitory receptor expressed on antigen activated T-cells that plays a critical role in the induction and maintenance of immune tolerance to self-antigens. Upon binding to its ligands CD274/PDCD1L1 (PD-L1) and CD273/PDCD1LG2 (PD-L2), PD1 is phosphorylated within its immunoreceptor tyrosine-based switch motif (ITSM), which facilitates the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2. PTPN11/SHP-2 then dephosphorylates key T-cell receptor (TCR) proximal signaling molecules, including ZAP70, PRKCQ/PKC theta and CD247/CD3 zeta, leading to the direct inhibition of T-cell activation. The PD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and evade destruction by the immune system, thereby facilitating tumor survival. Cat.No. Product Name Clone No. IF:{{item.impact}} Journal:{{item.journal}} ({{item.year}}) DOI:{{item.doi}} Reactivity:{{item.species}} Sample Type:{{item.sample_type}} Previous {{ page }} Next Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}} Previous {{ page }} Next [

UniProt: Q15116

Pathways: Cancer Immune Checkpoints